Tag: KYORIN
Japan – KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries
KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings, Inc., and Eisai Co., Ltd. have entered into a license agreement for development and distribution of vibegron, a therapeutic agent for overactive bladder, in four ASEAN (Association of Southeast Asian Nations) member states; Thailand, the Philippines, Malaysia and Brunei. Based on this agreement, Eisai will acquire exclusive development and marketing rights from KYORIN for the agent in the said four countries, and will be responsible for submitting a New Drug Application for the agent. Overactive bladder (OAB) is the name for a group of urinary symptoms characterized by urinary urgency, usually ... Read more